A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Study Identifier:

405-201-00021

ClinicalTrials.gov Identifier:

NCT05428033

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

ADHD

Study Drug

Drug: centanafadine capsule

Date

Jul 2022 - Mar 2025

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 4 - 12 Years

Requirements Information

Protocol Summary

This trial will be conducted to evaluate the efficacy of centanafadine QD XR versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.

Study Locations

Location

Status

Location

For additional information regarding sites, contact 844-687-8522

New York, New York, United States, 10012

Status

N/A